Host defense to RNA viruses depends on rapid intracellular recognition of viral RNA by two cytoplasmic RNA helicases: RIG-I and MDA5. RNA transfection experiments indicate that RIG-I responds to naked double-stranded RNAs (dsRNAs) with a triphosphorylated 5 0 (5 0 ppp) terminus. However, the identity of the RIG-I stimulating viral structures in an authentic infection context remains unresolved. We show that incoming viral nucleocapsids containing a 5 0 ppp dsRNA ''panhandle'' structure trigger antiviral signaling that commences with RIG-I, is mediated through the adaptor protein MAVS, and terminates with transcription factor IRF-3. Independent of mammalian cofactors or viral polymerase activity, RIG-I bound to viral nucleocapsids, underwent a conformational switch, and homo-oligomerized. Enzymatic probing and superresolution microscopy suggest that RIG-I interacts with the panhandle structure of the viral nucleocapsids. These results define cytoplasmic entry of nucleocapsids as the proximal RIG-I-sensitive step during infection and establish viral nucleocapsids with a 5 0 ppp dsRNA panhandle as a RIG-I activator.
SUMMARY
Host defense to RNA viruses depends on rapid intracellular recognition of viral RNA by two cytoplasmic RNA helicases: RIG-I and MDA5. RNA transfection experiments indicate that RIG-I responds to naked double-stranded RNAs (dsRNAs) with a triphosphorylated 5 0 (5 0 ppp) terminus. However, the identity of the RIG-I stimulating viral structures in an authentic infection context remains unresolved. We show that incoming viral nucleocapsids containing a 5 0 ppp dsRNA ''panhandle'' structure trigger antiviral signaling that commences with RIG-I, is mediated through the adaptor protein MAVS, and terminates with transcription factor IRF-3. Independent of mammalian cofactors or viral polymerase activity, RIG-I bound to viral nucleocapsids, underwent a conformational switch, and homo-oligomerized. Enzymatic probing and superresolution microscopy suggest that RIG-I interacts with the panhandle structure of the viral nucleocapsids. These results define cytoplasmic entry of nucleocapsids as the proximal RIG-I-sensitive step during infection and establish viral nucleocapsids with a 5 0 ppp dsRNA panhandle as a RIG-I activator.
INTRODUCTION
Host defenses to RNA viruses are dependent on rapid detection by pathogen recognition receptors (PRRs). Intracellular recognition of virus infection is mediated by two cytoplasmic RNA helicases: RIG-I and MDA5 (termed RIG-like receptors, RLRs) (Kato et al., 2011) . The binding of an RNA ligand to these PRRs leads to phosphorylation and dimerization of interferon regulated factor 3 (IRF-3), which subsequently activates genes for type I interferons (IFN-a/b) (Hiscott, 2007) . These cytokines trigger the expression of IFN-stimulated gene (ISG) products that have antiviral and immunomodulatory activities (Randall and Goodbourn, 2008) . The infection cycle of RNA viruses consists of the phases attachment, entry, messenger RNA (mRNA) transcription, genome replication, assembly, and exit. Negative-strand RNA viruses carry an RNA-dependent RNA polymerase (RdRp) within their particles and immediately start transcribing their genome after entering the cell. The protein products of this so-called primary transcription then drive the replication of the genome via a positive-sense intermediate. Positive-strand RNA viruses do not carry an RdRp in their particles and directly translate their genome after entry. The newly synthesized RdRp then produces a negative-sense intermediate, mRNA, and progeny genome. Usually, the genome of both negative-and positive-strand RNA viruses is packaged by a viral nucleocapsid protein (often called N).
Most studies on activation of RLRs were based either on infection with RNA viruses undergoing a full replication cycle or on transfection of cells with naked viral or synthetic RNAs. The infection experiments established that RIG-I and MDA5 recognize mostly nonoverlapping subsets of viruses (McCartney and Colonna, 2009 ). The RNA transfection experiments revealed that RIG-I responds to long double-stranded RNA (dsRNA) molecules, short dsRNAs with a triphosphorylated 5 0 (5 0 ppp) terminus, and poly-U/UC-rich sequences, whereas MDA5 activation is more dependent on branched dsRNA structures (Binder et al., 2011; Hornung et al., 2006; Kato et al., 2008; Pichlmair et al., 2006 Pichlmair et al., , 2009 Saito et al., 2008; Schlee et al., 2009; Schmidt et al., 2009 ). Despite these achievements, the question of the natural RLR ligands (i.e., which viral structures are stimulating the RLRs in the authentic infection context) is largely unsolved. Two recent RNA fractionation studies showed that full-length and shortened RNAs arising during genome replication of 5 0 ppp-RNA viruses are natural stimulators of RIG-I (Baum et al., 2010; Rehwinkel et al., 2010) . However, it remained open whether these RIG-I ligands were naked RNA side products of viral genome replication or whether RIG-I could also recognize nucleoprotein-encapsidated RNA, the main viral structure in the infected cell. Our study presented here addresses this problem and indicates that RIG-I is capable of reacting to incoming, encapsidated RNA virus genomes. This immediate early IFN response requires the viral 5 0 ppp dsRNA ''panhandle'' structure but is independent of viral RNA synthesis. RIG-I thereby directly interacts with the panhandle on the viral nucleocapsids, switches conformation, oligomerizes, and triggers the activation of IRF-3.
RESULTS
Our first aim was to identify the earliest infection step that triggers IFN induction. In the hope of drawing conclusions on the responsible viral determinant, we employed a set of RNA viruses with different genomic features. Dependent on the particular virus, a block of viral mRNA translation by cycloheximide (CHX) has different effects on primary transcription and genome replication (Table S1 available 
online).
Entry of Negative-Sense RNA Viruses Can Activate IFN Induction in the Absence of Replication Influenza A virus (FLUAV) and vesicular stomatitis virus (VSV) are negative-strand RNA viruses. Application of CHX allows particle attachment, entry of nucleocapsids, and primary transcription, but not genome replication ( Figure S1 ). We measured the virus-inducible genes for IFN-b and ISG56 in human A549 cells by real-time RT-PCR. Figure 1A shows that both FLUAV and VSV are strongly activating these genes, even when CHX was applied. Thus, an IFN response can occur before the viruses start replicating their genome.
To narrow down the IFN-relevant infection step, we repeated the experiment using Rift Valley fever virus (RVFV) and La Crosse virus (LACV). These bunyaviruses are peculiar in that their transcription depends on concurrent translation (Raju et al., 1989) . CHX treatment arrests viral primary transcription at a very early step, but had only a minor influence on IFN-b and ISG56 induction ( Figure 1B) . Apparently, not even a fully operating primary transcription is required for triggering an IFN response. Recent reports suggested that particle attachment or membrane fusion can activate an antiviral response (Holm et al., 2012; Noyce et al., 2011) , although other groups did not observe this in their systems (Handke et al., 2009; Spiropoulou et al., 2007; Stoltz and Klingströ m, 2010) . We employed several methods to study the involvement of particle attachment. First, we pretreated cells with NH 4 Cl, an agent that inhibits bunyaviral entry into the cytoplasm (Filone et al., 2006) but does not impede the IFN response ( Figure S2A ). As shown in Figure 1C , NH 4 Cl almost entirely abrogated the host response to RVFV. Similarly, three other bunyavirus entry inhibitors (de Boer et al., 2012) (Figure S2B-S2D ), as well as virus inactivation by b-propiolactone ( Figure S2E ) or UV irradiation ( Figure S2F ), all led to a reduction of IFN induction. In a complementary approach, we employed two types of virus-like particles (VLPs) of RVFV. Complete VLPs contain nucleocapsids with a reporter minigenome, whereas ''ghost'' VLPs have just the N protein inside (Figure S2G) . The complete VLPs, also called transcriptionally competent (tc-) VLPs (Hoenen et al., 2011) , are capable of primary transcription, but not of replication (Habjan et al., 2009a) . tc-VLPs triggered IFN-b and ISG56 expression, even under CHX ( Figure 1D ). Ghost VLPs, however, did not elicit any IFN response, although they bind equally well to the cells (Figure S2H ). These data indicate that, in our system, virus entry or primary transcription is necessary and sufficient for IFN induction.
The Immediate Early IFN Response Requires Viral 5 0 Triphosphate RNA and RIG-I All viruses used so far contained the RIG-I-activating 5 0 ppp group on their RNA genome (Habjan et al., 2008a; Hornung et al., 2006; Pichlmair et al., 2006) . To clarify the contribution of the genome end, we employed two RNA viruses that lack this feature (see Table S1 ). Prospect Hill virus (PHV; family Bunyaviridae) has a monophosphate at the 5 0 end (Garcin et al., 1995; Habjan et al., 2008a) . Semliki Forest virus (SFV; family Togaviridae) has a 5 0 cap structure (McInerney et al., 2005) . CHX inhibits PHV in the same way as the related RVFV or LACV ( Figure S1 ). SFV is a positive-strand RNA virus (i.e., its genome is directly translated after entry). In the absence of CHX, PHV minimally activated the IFN-b promoter and moderately activated ISG56 transcription, as expected (Prescott et al., 2005) , whereas the IFN response to SFV was similar to LACV ( Figure 2A ). Strikingly, application of CHX completely abrogated the IFN response to both PHV and SFV. In line with this, the transcription factor IRF-3 was activated under CHX-restricted infection with VSV or LACV, but not PHV or SFV ( Figure S3A-S3F) . Thus, IFN responses to incoming RNA virus nucleocapsids occur only if the genome contains a 5 0 ppp. To pin down the responsible RLR, we evaluated the influence of specific knockdowns. Cells were transfected with small interfering RNAs (siRNAs) for MDA5, RIG-I, or a control ( Figure S3G ), treated with CHX, and infected with VSV or LACV. Knockdown of RIG-I, but not of MDA5, impaired IFN induction by VSV and LACV nucleocapsids ( Figure 2B ). To bolster these findings, we utilized mouse embryo fibroblasts (MEFs) deficient in RIG-I or MDA5. Because these cells were extremely sensitive to CHX (data not shown), we employed tc-VLPs as a virus system halted at the stage of primary transcription. MEFs lacking MDA5 displayed similar host responses to tc-VLPs as WT MEFs ( Figure 2C ). MEFs lacking RIG-I, by contrast, completely lost their ability to respond ( Figure 2D ). Knockout of MAVS (Seth et al., 2005) , the adaptor common to MDA5 and RIG-I, had a similar impact (Figure S3H) . Taken together, these data suggest that nucleocapsids of 5 0 ppp RNA viruses activate an IFN response via the RIG-I-MAVS signaling cascade.
Activation of RIG-I
Binding of a target RNA to RIG-I triggers a conformational switch (Saito et al., 2007; Takahasi et al., 2008) and oligomerization (Binder et al., 2011; Saito et al., 2007) . The conformational switch is indicated by partial resistance to trypsin digestion. We observed that the full infection cycle of SFV, VSV, and LACV leads to the emergence of trypsin-resistant fragments of RIG-I ( Figure 3A ). When cells had been pretreated with CHX, VSV and LACV still triggered the conformational switch of RIG-I, whereas SFV infection had no effect ( Figure 3B ). The oligomerization of RIG-I was assayed by native PAGE. In uninfected cells, only monomers of RIG-I were detected ( Figure 3C ). Curiously, also in SFV-infected cells only monomeric RIG-I is present (Figure 3D ), although RIG-I switches conformation (see Figure 3A ). For the 5 0 ppp RNA viruses VSV and LACV, both the full and the CHX-aborted replication cycle resulted in RIG-I oligomerization ( Figures 3E and 3F ). The 5 0 -monophosphorylated PHV, by contrast, only weakly activated the conformational switch (Figure 3G) and not the oligomerization ( Figure 3H ). Taken together, these results suggest that RIG-I is rapidly and strongly activated by viral nucleocapsids in the absence of genome replication, provided the genome is carrying a 5 0 ppp group.
Interaction between RIG-I and Incoming Nucleocapsids
We wondered whether RIG-I could form a complex with viral 5 0 ppp RNA nucleocapsids. As an experimental system, we chose the setup closest to the immediate early phase (arrested primary transcription), namely infection with bunyaviruses such as LACV under CHX treatment. The N protein thereby served as a marker for viral nucleocapsids. Using confocal immunofluorescence Quantitative analysis revealed that LACV nucleocapsids colocalize with RIG-I in 51% of the cases but with the cytoplasmic control protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in 33% of the cases (data not shown). N/RIG-I colocalization was also observed in cells undergoing a full replication cycle (data not shown), in agreement with observations on FLUAV (Onomoto et al., 2012) . The incoming LACV nucleocapsids also colocalized with peroxisomes ( Figure S4B ), cytoplasmic organelles involved in immediate early activation of RIG-I (Dixit et al., 2010) . Coimmunoprecipitation demonstrated that RIG-I was capable of binding the incoming LACV nucleocapsids ( Figure 4B ). The same RIG-I/LACV nucleocapsid interaction was observed when a full replication cycle was allowed, whereas MDA5 did not interact under any condition (data not shown). Overexpressed N protein, by contrast, could not be precipitated via RIG-I ( Figure S4C ). We performed similar experiments with RVFV. Again, incoming nucleocapsids triggered the conformational switch and oligomerization of RIG-I and activated IRF-3 (Figure S4D) . Moreover, the nucleocapsids of RVFV colocalized ( Figure S4E ) and coprecipitated with RIG-I ( Figure S4F ). Strikingly, incoming nucleocapsids could be forced into a high-molecular-weight RIG-I complex. The ATP analog ADP,AlF 3 traps RIG-I in an RNA-bound closed conformation unable to cycle between the different states (Kowalinski et al., 2011) . When CHX-treated and infected cells were incubated with ADP,AlF 3 , the oligomers of RIG-I shifted from a smear into a single high-molecular-weight band ( Figure 4C , upper panels). Probing of the lysates for the viral N protein revealed a similar shift from an oligomeric state to a high-molecular-weight complex ( Figure 4C , lower panels). This was true for LACV as well as for RVFV, indicating a general phenomenon. Together, these findings demonstrate that RIG-I is able to associate with nucleocapsids of 5 0 ppp RNA viruses directly after entry into the cell, leading to RIG-I activation and innate immune signaling.
Nucleocapsid Binding and Activation of RIG-I Are Independent of Mammalian Cofactors
The RIG-I/nucleocapsid interaction could either be direct or mediated by one of the cellular cofactors of RIG-I (Kato et al., 2011; Kok et al., 2011; Miyashita et al., 2011) . To distinguish between these possibilities, we employed an insect cell system. Drosophila melanogaster cells are a useful tool to reconstitute mammalian signaling complexes in a background-free setting (Yang and Reth, 2012) and are infectable with RVFV (Kortekaas et al., 2011) . When human RIG-I was expressed in Drosophila D.mel-2 cells, conformational switching and oligomerization were observed after infection with RVFV ( Figures 5A and 5B ). RIG-I was also activated in vitro by mixing of lysates from RIG-I-transfected D.mel-2 cells with lysates of infected D.mel-2 cells ( Figure 5C ). Coimmunoprecipitation experiments demonstrated binding of RIG-I to viral nucleocapsids in the Drosophila system ( Figure 5D ). Again, this nucleocapsid interaction was independent of whether RIG-I contacted RVFV during authentic virus infection or whether lysates containing either RIG-I or RVFV nucleocapsids were mixed in vitro. Thus, activation and nucleocapsid interaction of RIG-I occur in a direct manner and without the contribution of a mammalian cofactor.
Nucleocapsid-Borne 5
0 ppp-dsRNA Is Necessary and Sufficient for RIG-I Activation Our experiments with bunyaviruses and CHX implicated that the transcriptional activity of nucleocapsids may not be relevant for RIG-I activation. However, CHX still allows some abortive transcription (Raju et al., 1989) . To clarify whether RIG-I requires this residual RNA synthesis, we performed several experiments. First, we depleted the cellular NTP pool with the compounds Brequinar (BRQ; inhibits pyrimidine synthesis), mycophenolic acid (MA; reduces GTP levels), pyrazofurin (PYF; reduces CTP and UTP levels), or cyclopentenylcytosine (CPEC; depletes the CTP pool) (Linke et al., 1996; Qing et al., 2010) . Each of these inhibitors affected viral RNA synthesis ( Figure S5A ). Nonetheless, even when combined with CHX, neither inhibitor diminished RIG-I activation by LACV ( Figure 6A ). In fact, some of the compounds slightly increased RIG-I activation and enhanced the activation of IRF-3 ( Figure 6A ). Second, we depleted Drosophila D.Mel-2 cell lysates containing either RIG-I or nucleocapsids from NTPs by dialysis. When these dialyzed lysates were mixed with each other, the conformational switch of RIG-I still occurred and was enhanced by adding back ATP ( Figure 6B ). Third, we employed nucleocapsids that had been isolated from purified virus particles. Dialyzed RIG-I-containing D.Mel-2 extracts were incubated with nucleocapsids of RVFV or LACV. The nucleocapsids clearly induced the conformational switch of RIG-I in vitro ( Figure 6C ). We conclude from these experiments that viral transcription is not necessary for triggering RIG-I. As outlined above, the genomic RNA of bunyaviruses forms a panhandle structure that has remarkable similarity with the optimal 5 0 ppp dsRNA ligand identified by transfection and in vitro binding experiments ( Figure S5B ). Indeed, destroying the dsRNA structures with RNase III or cleaving the triphosphates with a phosphatase abolished the ability of viral nucleocapsids to activate RIG-I ( Figures 6D and 6E) . Treatment with the single-stranded RNA-specific RNase A, by contrast, had no effect. Thus, a 5 0 ppp dsRNA structure is indeed necessary for the activation of RIG-I by nucleocapsids. 
A Single Site on the Nucleocapsids Is Contacted by RIG-I
We employed ground state depletion (GSD) microscopy to visualize the RIG-I/LACV nucleocapsid complex at 20 nm resolution. This technique allows the display of individual nucleocapsids in their characteristic pseudocircular shape (Figure 7 , green channel), which is caused by the dsRNA panhandle formation between the 5 0 and 3 0 genome ends (Obijeski et al., 1976) . Strikingly, accumulations of RIG-I are contacting nucleocapsids at a single site, lending the cocomplexes a ''diamond ring''-like appearance (Figure 7 , red channel). The negative control GAPDH, by contrast, appeared to be more distant and not accumulated at the nucleocapsids ( Figure S6 ). These observations add additional weight to our hypothesis that RIG-I binds the nucleocapsids via the terminal 5 0 ppp dsRNA panhandle.
DISCUSSION
The aim of our study was to clarify whether RIG-I is capable of recognizing the RNA contained within incoming viral nucleocapsids. Our results indicate that this is indeed the case. RIG-I was rapidly activated by viruses with the prototypical 5 0 ppp dsRNA panhandle structure, even when viral RNA synthesis was abolished. Moreover, we detected a direct, single-site interaction between RIG-I and nucleocapsids that was dependent on 5 0 ppp dsRNA. Thus, viral nucleocapsids containing a 5 0 ppp panhandle represent a pathogen-associated molecular pattern (PAMP) for RIG-I. These findings advance the proximal RIG-Isensitive step of the viral infection cycle from the late stage of genome replication (Baum et al., 2010; Rehwinkel et al., 2010) to the immediate early step of nucleocapsids entering the cytoplasm.
Erroneous, nonencapsidated replication products appear during infection with FLUAV (Vreede et al., 2004) . It is quite likely that such naked replication products Vreede et al., 2004) , along with defective interfering RNAs (Baum et al., 2010; Killip et al., 2011; Strahle et al., 2006) and newly formed nucleocapsids (this study), are responsible for RIG-I induction under a full viral multiplication cycle. Previous reports already demonstrated that genome replication is not an absolute requirement for IFN induction (Killip et al., 2012; Marcus and Sekellick, 1980) and that transfected nucleocapsids of the 5 0 ppp viruses measles and VSV can activate IRF-3 even if they are transcriptionally inactive (tenOever et al., 2002 (tenOever et al., , 2004 . None of these studies, however, had addressed the involvement of RIG-I or the requirement for a specific 5 0 genome end. Our work extends their conclusions by showing that incoming viral nucleocapsids can directly activate RIG-I, thus triggering a rapid innate immune response.
It remains to be shown how RIG-I manages to access the encapsidated viral RNA. Although the dsRNA-panhandle structure is covered by the viral polymerase (Resa-Infante et al., 2011) , some cytoplasmic exposure is necessary (e.g., to initiate mRNA transcription). The global presence of RIG-I in the cytoplasm and its high affinity for 5 0 ppp dsRNA may allow to rapidly entrap a panhandle, even if it is only briefly exposed. Our observation of an early and substantial formation of RIG-I oligomers in response to incoming nucleocapsids supports this hypothesis.
The standard model of RIG-I activation implies that ligand binding induces a conformational change followed by oligomerization (Kowalinski et al., 2011; Saito et al., 2007; Takahasi et al., 2008) . Interestingly, oligomerization seems not to be a strict consequence of the conformational switch. While infection with the negative-stranded 5 0 ppp-RNA viruses VSV, LACV, and RVFV triggers both the conformational switch and the oligomerization, infection with the positive-strand 5 0 capped RNA virus SFV triggers only the conformational switch. It is known that innate immune recognition of SFV occurs mainly through MDA5 with a modest contribution from RIG-I . VSV, LACV, and RVFV are mainly recognized by RIG-I (Habjan et al., 2008a; Kato et al., 2006; Verbruggen et al., 2011) . Thus, a weak RIG-I trigger like SFV may only cause the conformational switch, whereas stronger RIG-I triggers continue to the subsequent oligomerization.
We have introduced Drosophila cells as a tool to establish that RIG-I activation occurs independent of mammalian cofactors. In mammalian cells, RIG-I is fine-tuned by inhibitors and cofactors. The Drosophila cells, which can coexpress up to 12 different recombinant proteins (Yang and Reth, 2012) , hold promise as a system to reconstitute the RIG-I signaling complex for studying the details of its regulation.
The classical studies on PRRs and PAMPs involved the usage of purified RNA ligands. However, as we and others (Baum and García-Sastre, 2011; Kato et al., 2011) have pointed out, viral RNAs in their physiological context are complexed with host cell or viral proteins. Recent reports on the PRRs PKR and TLR3 provide increasing evidence that protein-bound RNA ligands are comparable or even more powerful PRR ligands than naked RNAs (Dauber et al., 2009; Lai et al., 2011) . It would be interesting to test other PRRs for activation by physiological nucleic acid-protein complexes.
In summary, our results indicate that RIG-I, the major intracellular PRR for viral pathogens, is capable of recognizing the 5 0 ppp-dsRNA of viral nucleocapsids. This enables a cytoplasmic response to incoming negative-strand RNA viruses at the earliest possible time point of infection.
EXPERIMENTAL PROCEDURES
Cells, Viruses, Plasmids, and Reagents A549, 293T, and MEFs deficient in RIG-I, MDA5 , or MAVS (Seth et al., 2005) were cultivated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS) at 37 C and 5% (Habjan et al., 2008b; Kuri et al., 2010) , and LACVdelNSs (Blakqori et al., 2007) were propagated on Vero cells. Plasmids pI.18_RVFV_N, pI.18_RVFV_L, pI.18_RVFV_M, and pHH21_RVFV_vMGFP were described previously (Habjan et al., 2008b (Habjan et al., , 2009a . Plasmid pRmHA3-RIG-I was constructed by cloning a PCR-generated RIG-I complementary DNA (cDNA) fragment into pRmHA3 (Bunch et al., 1988 ) using engineered 5 0 KpnI and 3 0 SalI restriction sites. Primer sequences are available upon request. CHX, NH 4 Cl, CuSO 4 , BRQ, and MA were from Sigma. PYF (NSC-143095) and CPEC (NSC-375575) were kindly obtained from the Drug Synthesis and Chemistry Branch of the National Cancer Institute.
Production of VLPs RVFV VLPs were generated as described previously (Habjan et al., 2009a) . Briefly, subconfluent monolayers of 293T cells in 90 mm dishes were transfected with 3 mg each of pI.18_RVFV_N, pI.18_RVFV_L, pI.18_RVFV_M, and pHH21_RVFV_vMGFP (tc-VLPs), or pI.18_RVFV_N and pI.18_RVFV_M only (ghost VLPs) using Nanofectin (PAA Laboratories). At 5 hr posttransfection, medium was changed and 48 hr later supernatants collected and clarified from cell debris by centrifugation (6,000 3 g, 10 min at 4 C). VLPs were concentrated with Amicon Ultra-15 (Millipore) Ultracel-100 kDa filter devices.
Infection of Cells
Cells grown to 90% confluency were inoculated for 1 hr with viruses or VLPs dissolved in 200 ml OptiMEM (Invitrogen; for mammalian cells) or Spodopan (for insect cells) at a multiplicity of infection (moi) of 5. FLUAVDNS1 was washed off with PBS, whereas for all other infections the inoculum was directly replaced with DMEM 5% FCS (mammalian cells) or Spodopan (insect cells). If required, cells were pretreated with inhibitors dissolved in complete medium for 1 hr (CHX, NH 4 Cl) or 24 hr (BRQ, MA, PYF, CPEC). The inhibitors were also added to the virus inoculum and the incubation medium.
Real-Time RT-PCR Cellular RNA was isolated with the NucleoSpin RNA II kit (Macherey-Nagel).
A total of 600 ng was used for cDNA synthesis and PCR employing the QuantiTect SYBR Green RT-PCR Kit (QIAGEN) and a LightCycler II (Roche). mRNAs of human and murine IFN-b and ISG56 were detected with specific QuantiTect primers (see Supplemental Information) and normalized against g-actin (human cells) or GAPDH (murine cells) using the ddCT method (Livak and Schmittgen, 2001) . Upregulation of inducible genes is depicted in relation to nonstimulated, noninfected (mock) cells.
siRNA Knockdown Knockdown of gene expression was achieved by 2-fold reverse transfection of siRNAs. siRNAs (25 nM each; see Supplemental Information) were diluted in 100 ml DMEM, mixed with 3 ml HiPerFect (QIAGEN), incubated for 10 min at room temperature, and dropped onto a 12-well plate. Then, 1.5 3 10 5 cells
in DMEM 10% FCS were seeded on top. After 48 hr at 37 C, cells were harvested, counted, and 1.5 3 10 5 cells were again reverse transfected as described.
Activation State of RIG-I
To assay the conformation of RIG-I, cells were lysed in PBS/0.5% Triton X-100 and incubated on ice for 10 min. Then, samples were sonified in a Branson 3200 Ultrasonic cleaner at 4 C for 10 min and centrifuged at 4 C for 10 min at 10,000 3 g. An aliquot of 25 mg of total protein in 10 ml PBS was digested for 25 min with 0.2 mg/ml L-1-tosylamido-2-phenylethyl chloromethyl ketonetreated trypsin (Sigma-Aldrich) at 37 C. Reaction was stopped by adding 53 sample buffer (250 mM Tris-HCl [pH 6.8], 10% SDS, 50% glycerol, 25% b-mercaptoethanol [b-ME], 0.5% bromphenol blue) and heating at 95 C for 5 min. Samples were subjected to 12% SDS-PAGE and western blot analysis using mouse monoclonal anti-RIG-I antibody (ALME-1; Enzo Life Sciences) at 1:1,000. Staining of the blot with 0.1% Ponceau S in 5% acetic acid served as a loading control.
To investigate the oligomerization of RIG-I, 50 mg of sonified cell lysate in native loading buffer (50 mM Tris-HCl [pH 6.8], 10% glycerol, 0.1% bromphenol blue) was loaded onto a nondenaturing 8% polyacrylamide gel. Proteins were separated by electrophoresis with 50 mM Tris-NaOH (pH 9.0), 384 mM glycin as anode buffer and 50 mM Tris (pH 8.3), 384 mM glycin, 1% sodium deoxycholate as cathode buffer. Western blot analysis was performed as outlined above.
Immunofluorescence Assays Cells were grown on coverslips to 30%-50% confluency, infected, and incubated for the indicated time. Cells were fixed with 3% paraformaldehyde, permeabilized with 0.5% Triton X-100 in PBS, and washed three times with PBS. Primary antibodies were diluted in PBS/1% FCS. Primary antibodies were either rabbit polyclonal anti-LACV N (1:1,000) (Blakqori et al., 2007) or rabbit polyclonal anti-RVFV N (1:1,000) (Lorenzo et al., 2008) combined with mouse polyclonal anti-human RIG-I (1:200) (Baum et al., 2010) . After 1 hr incubation at room temperature, coverslips were washed three times in PBS then treated with goat anti-rabbit Cy2 and goat anti-mouse Cy3 at a dilution of 1:200. After washing three times in PBS, coverslips were mounted with Fluorsave solution (Calbiochem) and examined using a Leica SP5 confocal microscope.
For the superresolution microscopy, a Leica SR GSD microscope was used. Samples were prepared as described for confocal microscopy except that goat anti-rabbit Alexa Fluor 488 (LACV N) and goat anti-mouse Alexa Fluor 647 (RIG-I) were employed as secondary antibody antibodies. Samples were embedded in freshly prepared 100 mM b-mercaptoethylamine in PBS (pH 7.4) directly before imaging.
Coimmunoprecipitation Assays
Cells grown in two T175 flasks were scraped off in 10 ml PBS, centrifuged at low speed, and the pellets lysed in 1,050 ml RIPA buffer (prepared with DEPC-treated H 2 O) containing protease inhibitors, incubated on ice for 30 min and centrifuged at 4 C for 10 min at 10,000 3 g. Supernatants were transferred to fresh tubes and 10% kept as input control. The remaining 90% of the lysates were subjected to immunoprecipitation (IP) using Dynabeads (Invitrogen). In parallel, 1.5 mg beads per IP were coupled with the appropriate antibodies using the Dynabeads antibody coupling kit (Invitrogen).
For the anti-p21 and anti-RIG-I IPs, beads were coupled with rabbit polyclonal anti-mouse antibody (DAKO); for the anti-LACV N IP, beads were coupled with rabbit polyclonal anti-LACV N (each at a 1:200 dilution per IP); and for Figure S6 .
the anti-RVFV N IP, beads were coupled with mouse polyclonal anti-N serum (Habjan et al., 2009b) for 20 hr at 37 C. After antibody coupling, beads were washed two times with RIPA buffer, and the anti-mouse antibody beads were further incubated with mouse monoclonal anti-p21 (Santa Cruz Biotechnology) or mouse monoclonal anti-RIG-I antibody ALME-1 at a 1:200 dilution in RIPA buffer for 2 hr at 4 C. The beads were then incubated with the lysates for 2 hr at 4 C and the immunoprecipitates washed three times with RIPA buffer and then eluted with sample buffer (50 mM Tris-HCl [pH 6.8], 2% SDS, 10% glycerol, 5% b-ME, 0.1% bromphenol blue) for 5 min at 95 C. Eluates were analyzed by western blotting using rabbit polyclonal anti-LACV N or anti-RVFV N antisera (1:1,000), mouse monoclonal anti-RIG-I antibody ALME-1 (1:1,000), or mouse monoclonal anti-p21 (1:500). Protein A horseradish peroxidase conjugate (Millipore; 1:10,000) was used for detection.
ADP-Aluminum Fluoride Trapping ADP,AlF 3 trapping was performed essentially as described elsewhere (Chaney et al., 2001) . Briefly, 50 mg cell protein was prepared in STA buffer (25 mM Tris-acetate [pH 8.0], 8 mM Mg-acetate, 10 mM KCl, 3.5% w/v PEG 6000, 1 mM DTT) with 0.2 mM ADP and 10 mM NaF and incubated at 37 C for 5 min. After addition of 0.4 mM AlCl 3 , the reactions were incubated for further 10 min and then supplemented with native loading buffer (50 mM Tris-HCl [pH 6.8], 10% glycerol, 0.1% bromophenol blue). Native gel electrophoresis and western blot analysis were performed as described above.
Expression of RIG-I in Drosophila Cells D.Mel-2 cells (1 3 10 7 ) resuspended in 10 ml Spodopan were transfected with 16 mg pRmHa3-RIG-I plasmid mixed with 48 ml Cellfectin (Invitrogen) and incubated at 28 C in T75 flasks. RIG-I expression was induced 48 hr later with 1 mM CuSO 4 , and 24 hr later cells were scraped off in 10 ml PBS. Cells were pelleted by 5 min centrifugation at 100 3 g and resuspended in 800 ml RIPA buffer (for IPs) or in 150 ml 0.5% Triton X-100 in PBS (for RIG-I assays). The suspensions were incubated for 10 min at 4 C and centrifuged at 10,000 3 g, and the supernatants were kept at 4 C.
Dialysis and ATP Supplementation of Cell Lysates
Visking dialysis tubing 27/32 with a diameter of 21 mm (Serva Electrophoresis) was used to deplete cell lysates from low-molecular-weight compounds. The membrane tubes were activated by submerging in H 2 O and boiling for 1 min in the microwave oven, followed by a transfer into H 2 O at room temperature. For cell lysates, 100 ml was dialyzed at 4 C against PBS in 1 ml Eppendorf tubes covered with the dialysis membrane. For nucleocapsids, 10 ml was dialyzed using 200 ml PCR tubes. The buffer was exchanged after 1 hr, 12 hr, and then again 1 hr later. To test the contribution of ATP, lysates or nucleocapsids were first mixed and then incubated with or without 1 mM ATP for 1 hr at 37 C.
The RIG-I conformational switch assay was performed as indicated above.
Purification of Viral Nucleocapsids BHK cells seeded in ten T175 flasks were infected with virus at an moi of 0.01. Cell supernatants were harvested at 3 days later and virions purified by centrifugation through a 30% glycerol cushion at 25,000 rpm for 1.5 hr at 4 C in a SW-32 rotor. Pellets were resuspended in hypotonic lysis buffer (10 mM Tris/HCl [pH 7.8], 150 mM NaCl, 1 mM EDTA, 1% NP40) in the presence of complete protease inhibitors (Roche). Nucleocapsids were purified in a CsCl gradient as described elsewhere (Mavrakis et al., 2002) , with minor modifications. Briefly, the cleared lysate was loaded on top of a continuous 20%-40% CsCl gradient in 20 mM Tris/HCl (pH 7.9), 200 mM NaCl, centrifuged at 52,000 rpm for 2 hr at 12 C in a SW60 rotor, and the recovered fraction pelleted at 45,000 rpm for 1 hr at 4 C in a TLA45 rotor. Nucleocapsids were resuspended in PBS and dialyzed against PBS to remove residual CsCl. Nucleocapsid-containing fractions were identified by SDS-PAGE with Coomassie blue staining and western blot analysis.
Enzymatic Treatment of Lysates
Dialyzed lysates of RVFV-infected D.Mel-2 cells (50 mg protein in 10 ml) or nucleocapsids were supplemented with 1 mM ATP and incubated either with 5 mg RNase A, 1 U RNase III, or 2 U shrimp alkaline phosphatase (SAP) for 1 hr at 37 C. Samples were then mixed 1:1 with dialyzed lysates from RIG-I-expressing D.Mel-2 cells (50 mg protein in 10 ml) and incubated for 1 hr at 37 C. The RIG-I conformation assay was performed with half of the sample, whereas the other half was kept as input control.
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